vs

Side-by-side financial comparison of SBA Communications (SBAC) and West Pharmaceutical Services (WST). Click either name above to swap in a different company.

West Pharmaceutical Services is the larger business by last-quarter revenue ($805.0M vs $703.4M, roughly 1.1× SBA Communications). SBA Communications runs the higher net margin — 26.3% vs 16.4%, a 9.9% gap on every dollar of revenue. On growth, West Pharmaceutical Services posted the faster year-over-year revenue change (7.5% vs -1.6%). Over the past eight quarters, West Pharmaceutical Services's revenue compounded faster (7.6% CAGR vs 3.2%).

SBA Communications Corporation is a real estate investment trust which owns and operates wireless infrastructure in the United States, Canada, Central America, South America, and South Africa. It was founded in 1989 as Steven Bernstein and Associates by Steven Bernstein.

West Pharmaceutical Services, Inc. is a designer and manufacturer of injectable pharmaceutical packaging and delivery systems. Founded in 1923 by Herman O. West and J.R. Wike of Philadelphia, the company is headquartered in Exton, Pennsylvania. In its early years of development, West produced rubber components for packaging injectable drugs, providing a sterile environment for the producers of penicillin and insulin.

SBAC vs WST — Head-to-Head

Bigger by revenue
WST
WST
1.1× larger
WST
$805.0M
$703.4M
SBAC
Growing faster (revenue YoY)
WST
WST
+9.1% gap
WST
7.5%
-1.6%
SBAC
Higher net margin
SBAC
SBAC
9.9% more per $
SBAC
26.3%
16.4%
WST
Faster 2-yr revenue CAGR
WST
WST
Annualised
WST
7.6%
3.2%
SBAC

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
SBAC
SBAC
WST
WST
Revenue
$703.4M
$805.0M
Net Profit
$184.9M
$132.1M
Gross Margin
37.8%
Operating Margin
48.7%
19.5%
Net Margin
26.3%
16.4%
Revenue YoY
-1.6%
7.5%
Net Profit YoY
-15.1%
1.5%
EPS (diluted)
$1.74
$1.82

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
SBAC
SBAC
WST
WST
Q1 26
$703.4M
Q4 25
$719.6M
$805.0M
Q3 25
$732.3M
$804.6M
Q2 25
$699.0M
$766.5M
Q1 25
$664.2M
$698.0M
Q4 24
$693.7M
$748.8M
Q3 24
$667.6M
$746.9M
Q2 24
$660.5M
$702.1M
Net Profit
SBAC
SBAC
WST
WST
Q1 26
$184.9M
Q4 25
$370.4M
$132.1M
Q3 25
$236.8M
$140.0M
Q2 25
$225.8M
$131.8M
Q1 25
$220.7M
$89.8M
Q4 24
$178.8M
$130.1M
Q3 24
$258.5M
$136.0M
Q2 24
$162.8M
$111.3M
Gross Margin
SBAC
SBAC
WST
WST
Q1 26
Q4 25
75.6%
37.8%
Q3 25
74.1%
36.6%
Q2 25
75.4%
35.7%
Q1 25
76.9%
33.2%
Q4 24
78.1%
36.5%
Q3 24
77.5%
35.4%
Q2 24
78.6%
32.8%
Operating Margin
SBAC
SBAC
WST
WST
Q1 26
48.7%
Q4 25
41.5%
19.5%
Q3 25
51.1%
20.8%
Q2 25
47.9%
20.1%
Q1 25
50.4%
15.3%
Q4 24
55.1%
21.3%
Q3 24
56.3%
21.6%
Q2 24
53.7%
18.0%
Net Margin
SBAC
SBAC
WST
WST
Q1 26
26.3%
Q4 25
51.5%
16.4%
Q3 25
32.3%
17.4%
Q2 25
32.3%
17.2%
Q1 25
33.2%
12.9%
Q4 24
25.8%
17.4%
Q3 24
38.7%
18.2%
Q2 24
24.7%
15.9%
EPS (diluted)
SBAC
SBAC
WST
WST
Q1 26
$1.74
Q4 25
$3.47
$1.82
Q3 25
$2.20
$1.92
Q2 25
$2.09
$1.82
Q1 25
$2.04
$1.23
Q4 24
$1.61
$1.78
Q3 24
$2.40
$1.85
Q2 24
$1.51
$1.51

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
SBAC
SBAC
WST
WST
Cash + ST InvestmentsLiquidity on hand
$269.1M
$791.3M
Total DebtLower is stronger
$2.7B
$202.8M
Stockholders' EquityBook value
$3.2B
Total Assets
$11.7B
$4.3B
Debt / EquityLower = less leverage
0.06×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
SBAC
SBAC
WST
WST
Q1 26
$269.1M
Q4 25
$271.2M
$791.3M
Q3 25
$431.1M
$628.5M
Q2 25
$276.8M
$509.7M
Q1 25
$702.2M
$404.2M
Q4 24
$444.4M
$484.6M
Q3 24
$202.6M
$490.9M
Q2 24
$250.9M
$446.2M
Total Debt
SBAC
SBAC
WST
WST
Q1 26
$2.7B
Q4 25
$12.9B
$202.8M
Q3 25
$12.7B
$202.7M
Q2 25
$12.5B
$202.6M
Q1 25
$12.4B
$202.6M
Q4 24
$13.6B
$202.6M
Q3 24
$12.3B
$202.6M
Q2 24
$12.3B
$205.8M
Stockholders' Equity
SBAC
SBAC
WST
WST
Q1 26
Q4 25
$-4.9B
$3.2B
Q3 25
$-4.9B
$3.1B
Q2 25
$-4.9B
$2.9B
Q1 25
$-5.0B
$2.7B
Q4 24
$-5.1B
$2.7B
Q3 24
$-5.2B
$2.8B
Q2 24
$-5.3B
$2.6B
Total Assets
SBAC
SBAC
WST
WST
Q1 26
$11.7B
Q4 25
$11.6B
$4.3B
Q3 25
$11.3B
$4.1B
Q2 25
$10.8B
$4.0B
Q1 25
$10.4B
$3.6B
Q4 24
$11.4B
$3.6B
Q3 24
$10.2B
$3.7B
Q2 24
$9.8B
$3.5B
Debt / Equity
SBAC
SBAC
WST
WST
Q1 26
Q4 25
0.06×
Q3 25
0.07×
Q2 25
0.07×
Q1 25
0.08×
Q4 24
0.08×
Q3 24
0.07×
Q2 24
0.08×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
SBAC
SBAC
WST
WST
Operating Cash FlowLast quarter
$255.1M
$251.1M
Free Cash FlowOCF − Capex
$175.0M
FCF MarginFCF / Revenue
21.7%
Capex IntensityCapex / Revenue
9.5%
9.5%
Cash ConversionOCF / Net Profit
1.38×
1.90×
TTM Free Cash FlowTrailing 4 quarters
$468.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
SBAC
SBAC
WST
WST
Q1 26
$255.1M
Q4 25
$1.3B
$251.1M
Q3 25
$318.0M
$197.2M
Q2 25
$368.1M
$177.1M
Q1 25
$301.2M
$129.4M
Q4 24
$1.3B
$190.1M
Q3 24
$304.7M
$180.1M
Q2 24
$425.6M
$165.0M
Free Cash Flow
SBAC
SBAC
WST
WST
Q1 26
Q4 25
$833.3M
$175.0M
Q3 25
$258.0M
$133.9M
Q2 25
$312.2M
$101.9M
Q1 25
$255.0M
$58.1M
Q4 24
$1.2B
$85.2M
Q3 24
$239.9M
$98.8M
Q2 24
$375.6M
$64.8M
FCF Margin
SBAC
SBAC
WST
WST
Q1 26
Q4 25
115.8%
21.7%
Q3 25
35.2%
16.6%
Q2 25
44.7%
13.3%
Q1 25
38.4%
8.3%
Q4 24
179.9%
11.4%
Q3 24
35.9%
13.2%
Q2 24
56.9%
9.2%
Capex Intensity
SBAC
SBAC
WST
WST
Q1 26
9.5%
Q4 25
63.7%
9.5%
Q3 25
8.2%
7.9%
Q2 25
8.0%
9.8%
Q1 25
7.0%
10.2%
Q4 24
12.6%
14.0%
Q3 24
9.7%
10.9%
Q2 24
7.6%
14.3%
Cash Conversion
SBAC
SBAC
WST
WST
Q1 26
1.38×
Q4 25
3.49×
1.90×
Q3 25
1.34×
1.41×
Q2 25
1.63×
1.34×
Q1 25
1.36×
1.44×
Q4 24
7.47×
1.46×
Q3 24
1.18×
1.32×
Q2 24
2.61×
1.48×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

SBAC
SBAC

Site leasing$656.1M93%
Site development$47.3M7%

WST
WST

Proprietary Products$661.8M82%
Contract Manufactured Products$143.2M18%
Affiliated Entity$3.3M0%

Related Comparisons